Author: admin

DelveInsight’s, “Overactive Bladder Pipeline Insights 2025” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Overactive Bladder pipeline landscape. It covers the Overactive Bladder pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Overactive Bladder pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Stay ahead with the latest insights! Download DelveInsight’s comprehensive Overactive Bladder Pipeline Report to explore emerging therapies, key companies, and future treatment landscapes @ Overactive Bladder Pipeline Outlook Report

Key Takeaways from the Overactive Bladder Pipeline Report

• In January 2025, Imbrium Therapeutics L.P. (“Imbrium”), a subsidiary of Purdue Pharma L.P. (“Purdue”), announced results from a Phase Ib clinical signal detection study evaluating the safety and efficacy of the novel investigational treatmentsunobinop in patients with overactive bladder syndrome.
• DelveInsight’s Overactive Bladder pipeline report depicts a robust space with 15+ active players working to develop 15+ pipeline therapies for Overactive Bladder treatment.
• The leading Overactive Bladder Companies such as Dong-A ST Co., Ltd., AbbVie/Medytox, Urovant Sciences, Taiho Pharma, Velicept Therapeutics and others.
• Promising Overactive Bladder Pipeline Therapies such as GSK1358820, YM178, Fesoterodine 8 mg, Vibegron, Tolterodine ER, Solifenacin Succinate, Oxybutynin chloride OROS, VESIcare®, Fesoterodine, and others.

Discover how the Overactive Bladder treatment paradigm is evolving. Access DelveInsight’s in-depth Overactive Bladder Pipeline Analysis for a closer look at promising breakthroughs @ Overactive Bladder Clinical Trials and Studies

Overactive Bladder Emerging Drugs Profile

• Neuronox: AbbVie/Medytox

Neuronox, an acetylcholine inhibitor is being developed by Medy-Tox for the treatment of the Overactive Bladder. The active ingredients involve Clostridium botulinum toxin type A. It is currently in the phase III stage of development. In September 2020, US drugmaker Allergan entered into a license agreement with South Korea’s Medytox under the terms of which, on closing, Allergan would pay Medytox an upfront of USD 65 million and Medytox would grant Allergan exclusive rights, worldwide outside of Korea, to develop and, if approved, commercialise certain neurotoxin product candidates currently in development, including a potential liquid-injectable product. In May 2020, AbbVie announced that it had finished its acquisition of Allergan plc following receipt of regulatory approval from all government authorities needed by the transaction agreement and approval by the Irish High Court.

• URO-902: Urovant Sciences

Urovant Sciences is developing URO-902 for the treatment of the Overactive Bladder. URO-902 has the potential to be the first gene therapy for OAB patients. This innovative treatment has the capability to tackle an unmet need for patients who have failed oral pharmacologic therapies and are concerned with potential urinary retention or surgical interventions pertinent to existing third-line OAB treatments. It is currently in the phase II stage of development.

The Overactive Bladder Pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Overactive Bladder with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Overactive Bladder Treatment.
• Overactive Bladder Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Overactive Bladder Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Overactive Bladder market.

Get a detailed analysis of the latest innovations in the Overactive Bladder pipeline. Explore DelveInsight’s expert-driven report today! @ Overactive Bladder Unmet Needs

Overactive Bladder Companies

Dong-A ST Co., Ltd., AbbVie/Medytox, Urovant Sciences, Taiho Pharma, Velicept Therapeutics and others.

Overactive Bladder Pipeline Report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Overactive Bladder Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

Download DelveInsight’s latest report to gain strategic insights into upcoming Overactive Bladder Therapies and key Developments @ Overactive Bladder Market Drivers and Barriers, and Future Perspectives

Scope of the Overactive Bladder Pipeline Report

• Coverage- Global
• Overactive Bladder Companies- Dong-A ST Co., Ltd., AbbVie/Medytox, Urovant Sciences, Taiho Pharma, Velicept Therapeutics and others.
• Overactive Bladder Pipeline Therapies- GSK1358820, YM178, Fesoterodine 8 mg, Vibegron, Tolterodine ER, Solifenacin Succinate, Oxybutynin chloride OROS, VESIcare®, Fesoterodine, and others.
• Overactive Bladder Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Overactive Bladder Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Which companies are leading the race in Overactive Bladder drug development? Find out in DelveInsight’s exclusive pipeline report—access it now! @ Overactive Bladder Emerging Drugs and Major Companies

Table of Contents

1. Introduction
2. Executive Summary
3. Overactive Bladder: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Overactive Bladder– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Neuronox: AbbVie/Medytox
9. Mid Stage Products (Phase II)
10. URO-902: Sumitovant Biopharma
11. Early Stage Products (Phase I)
12. Drug Name: Company Name
13. Preclinical and Discovery Stage Products
14. Drug Name: Company Name
15. Inactive Products
16. Overactive Bladder Key Companies
17. Overactive Bladder Key Products
18. Overactive Bladder- Unmet Needs
19. Overactive Bladder- Market Drivers and Barriers
20. Overactive Bladder- Future Perspectives and Conclusion
21. Overactive Bladder Analyst Views
22. Overactive Bladder Key Companies
23. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/overactive-bladder-pipeline-insight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Overactive Bladder Pipeline Outlook Report 2025: Key 15+ Companies and Breakthrough Therapies Shaping the Future Landscape

DelveInsight’s, “Dystrophic Epidermolysis Bullosa Pipeline Insight, 2025,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Dystrophic Epidermolysis Bullosa pipeline landscape. It covers the Dystrophic Epidermolysis Bullosa pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Dystrophic Epidermolysis Bullosa pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Stay ahead with the latest insights! Download DelveInsight’s comprehensive Dystrophic Epidermolysis Bullosa Pipeline Report to explore emerging therapies, key companies, and future treatment landscapes @ Dystrophic Epidermolysis Bullosa Pipeline Outlook Report

Key Takeaways from the Dystrophic Epidermolysis Bullosa Pipeline Report

• In August 2025, Krystal Biotech Inc. announced a Phase 3 study, to evaluate the safety and efficacy of KB803 versus matched placebo in pediatric and adult subjects with recurrent corneal abrasions due to dystrophic epidermolysis bullosa (DEB).
• In August 2025, Castle Creek Biosciences LLC conducted a study is to determine whether administration of D-Fi in addition to standard of care improves wound healing as compared to standard of care alone (control) in children, adolescents, and adults with Dystrophic Epidermolysis Bullosa.
• DelveInsight’s Dystrophic Epidermolysis Bullosa pipeline report depicts a robust space with 15+ active players working to develop 15+ pipeline therapies for Dystrophic Epidermolysis Bullosa treatment.
• The leading Dystrophic Epidermolysis Bullosa Companies such as Phoenix Tissue Repair, Castle Creek Biosciences, Phoenicis Therapeutics, Aegle Therapeutics, RHEACELL GmbH & Co. KG, Anterogen Co., Ltd., Abeona Therapeutics, Inc, InMed Pharmaceuticals, BridgeBio Inc., Eloxx Pharmaceuticals, Relief Therapeutics, Quoin Pharmaceuticals and others.
• Promising Dystrophic Epidermolysis Bullosa Pipeline Therapies such as KB803, AGLE-102, EB-101, PTR-01, Oleogel-S10, INM-755 (cannabinol) cream, and others.

Discover how the Dystrophic Epidermolysis Bullosa treatment paradigm is evolving. Access DelveInsight’s in-depth pipeline analysis for a closer look at promising breakthroughs @ Dystrophic Epidermolysis Bullosa Clinical Trials and Studies

Dystrophic Epidermolysis Bullosa Emerging Drugs Profile

• PTR-01: Phoenix Tissue Repair

Phoenix Tissue Repair is advancing an investigational therapy known as PTR-01, a systemic recombinant collagen type VII (rC7) for the treatment of Recessive Dystrophic Epidermolysis Bullosa. rC7 is a potentially disease-modifying drug that is delivered intravenously to patients, replacing defective collagen type VII with healthy collagen at the sites where it is needed both internally and externally. Phoenix Tissue Repair acquired worldwide rights to PTR-01 from Shire Plc in 2017 and has initiated its first clinical trial. Preclinical studies of PTR-01 have shown that it selectively anchors in the skin and other tissues affected by an absence of collagen type VII. In four animal models of the disease, intravenous injections of PTR-01 promoted healing of DEB wounds. These experiments have shown improvements in tissue structure, disease presentation and survival, indicating a restoration of natural skin architecture.

• FCX-007: Castle Creek Biosciences

D-Fi, also known as FCX-007, (dabocemagene autoficel), is being developed as an ex vivo, autologous cell-based gene therapy to address the deficiency of functional COL7 in patients with dystrophic epidermolysis bullosa (DEB). D-Fi has been clinically studied in a Phase 1/2 clinical study (NCT02810951), which assessed 6 patients with RDEB. In this study, 80% (8/10) of treated chronic wounds demonstrated complete wound healing 12 weeks after the first injection of D-Fi, while none of the untreated wounds were healed. D-Fi was well tolerated post-administration with few reports of temporary redness or discoloration at the injection site. D-Fi is currently in Phase 3 clinical development for the localized treatment of chronic wounds in individuals with RDEB.

The Dystrophic Epidermolysis Bullosa Pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Dystrophic Epidermolysis Bullosa with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Dystrophic Epidermolysis Bullosa Treatment.
• Dystrophic Epidermolysis Bullosa Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Dystrophic Epidermolysis Bullosa Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Dystrophic Epidermolysis Bullosa market.

Get a detailed analysis of the latest innovations in the Dystrophic Epidermolysis Bullosa pipeline. Explore DelveInsight’s expert-driven report today! @ Dystrophic Epidermolysis Bullosa Unmet Needs

Dystrophic Epidermolysis Bullosa Companies

Phoenix Tissue Repair, Castle Creek Biosciences, Phoenicis Therapeutics, Aegle Therapeutics, RHEACELL GmbH & Co. KG, Anterogen Co., Ltd., Abeona Therapeutics, Inc, InMed Pharmaceuticals, BridgeBio Inc., Eloxx Pharmaceuticals, Relief Therapeutics, Quoin Pharmaceuticals and others.

​​Dystrophic Epidermolysis Bullosa pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous

Dystrophic Epidermolysis Bullosa Products have been categorized under various Molecule types such as

• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine

Download DelveInsight’s latest report to gain strategic insights into upcoming Dystrophic Epidermolysis Bullosa Therapies and key Developments @ Dystrophic Epidermolysis Bullosa Market Drivers and Barriers, and Future Perspectives

Scope of the Dystrophic Epidermolysis Bullosa Pipeline Report

• Coverage- Global
• Dystrophic Epidermolysis Bullosa Companies- Phoenix Tissue Repair, Castle Creek Biosciences, Phoenicis Therapeutics, Aegle Therapeutics, RHEACELL GmbH & Co. KG, Anterogen Co., Ltd., Abeona Therapeutics, Inc, InMed Pharmaceuticals, BridgeBio Inc., Eloxx Pharmaceuticals, Relief Therapeutics, Quoin Pharmaceuticals and others.
• Dystrophic Epidermolysis Bullosa Pipeline Therapies- KB803, AGLE-102, EB-101, PTR-01, Oleogel-S10, INM-755 (cannabinol) cream, and others.
• Dystrophic Epidermolysis Bullosa Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Dystrophic Epidermolysis Bullosa Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Which companies are leading the race in Dystrophic Epidermolysis Bullosa drug development? Find out in DelveInsight’s exclusive pipeline report—access it now! @ Dystrophic Epidermolysis Bullosa Emerging Drugs and Major Companies

Table of Contents

1. Introduction
2. Executive Summary
3. Dystrophic Epidermolysis Bullosa: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Dystrophic Epidermolysis Bullosa – DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. FCX-007: Castle Creek Biosciences
9. Mid Stage Products (Phase II)
10. PTR-01: Phoenix Tissue Repair
11. Early Stage Products (Phase I/II)
12. PTW-002: Phoenicis Therapeutics
13. Preclinical and Discovery Stage Products
14. Drug name: Company name
15. Inactive Products
16. Dystrophic Epidermolysis Bullosa Key Companies
17. Dystrophic Epidermolysis Bullosa Key Products
18. Dystrophic Epidermolysis Bullosa- Unmet Needs
19. Dystrophic Epidermolysis Bullosa- Market Drivers and Barriers
20. Dystrophic Epidermolysis Bullosa- Future Perspectives and Conclusion
21. Dystrophic Epidermolysis Bullosa Analyst Views
22. Dystrophic Epidermolysis Bullosa Key Companies
23. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/dystrophic-epidermolysis-bullosa-pipeline-insight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Dystrophic Epidermolysis Bullosa Pipeline Outlook Report 2025: Key 15+ Companies and Breakthrough Therapies Shaping the Future Landscape

DelveInsight’s “Mesothelioma Pipeline Insight 2025” report provides comprehensive insights about 45+ companies and 50+ pipeline drugs in the mesothelioma pipeline landscape. It covers the Mesothelioma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Mesothelioma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Download our comprehensive report now to explore clinical-stage developments and strategic collaborations transforming the industry! @ Mesothelioma Pipeline Outlook Report

Key Takeaways from the Mesothelioma Pipeline Report

• In August 2025, AstraZeneca announced a phase III study to determine the efficacy and safety of Volrustomig (MEDI5752) + Carboplatin + Pemetrexed vs the investigator’s choice of platinum + Pemetrexed or Nivolumab + Ipilimumab in participants with unresectable pleural mesothelioma.
• In August 2025, Epizyme Inc. conducted a study that will provide continuing availability to tazemetostat for people who have previously completed participation in a tazemetostat study, either with monotherapy (single drug treatment) or combination therapy.
• DelveInsight’s Mesothelioma pipeline report depicts a robust space with 45+ active players working to develop 50+ pipeline therapies for Mesothelioma treatment.
• The leading Mesothelioma Companies such as Polaris Pharmaceuticals, AstraZeneca, MedImmune LLC, Takeda, RS Oncology LLC, Vivace Therapeutics, Inc., VM Oncology, LLC, KaliVir Immunotherapeutics, UTC Therapeutics Inc., Tango Therapeutics, Inc., Verismo Therapeutics, SpringWorks Therapeutics, Inc., Gilead Sciences, Nurix Therapeutics, Inc., Amphera BV, Merck Sharp & Dohme LLC, Constellation Pharmaceuticals, BridGene Biosciences Inc., Aromics Therapeutics, and Ascentage Pharma Group Inc. and others.
• Promising Mesothelioma Therapies such as Pembrolizumab, Lenvatinib, Nivolumab, Ipilimumab, ZD1839, Zometa, Durvalumab, and others.

Learn how leading Mesothelioma Companies are positioning themselves for success in the evolving pharmaceutical market—access the full report today!” @ Mesothelioma Clinical Trials Assessment

Mesothelioma Emerging Drugs

• Pegargiminase: Polaris Pharmaceuticals

Pegargiminase (ADI‑PEG 20), is a biologic in late-stage clinical development for a wide range of cancers. It is a novel therapeutic protein being developed for cancers with a unique metabolic trait. Pegargiminase deprives the cancer cells of the amino acid Arginine by converting plasma-borne arginine into citrulline. At the core of their deficiency is a down-regulation of Argininosuccinate Synthase (ASS1), an enzyme needed to synthesize arginine. To survive, the cancer cells must “rewire” their metabolism. This exerts a stress on the cells that renders them more susceptible to conventional chemotherapies. Pegargiminase has also gained Orphan Drug Designation for mesothelioma both in the U.S. and in Europe. Currently, the drug is in Preregistration stage of its development for the treatment of Mesothelioma.

• Volrustomig: AstraZeneca

Volrustomig is an engineered Fragment Crystallizable (Fc) domain bispecific human immunoglobulin G1 (IgG1) monoclonal antibody directed against the human negative immunoregulatory checkpoint receptors programmed cell death protein 1 (PD-1; PDCD1; CD279) and cytotoxic T-lymphocyte-associated antigen 4 (CTLA4; CTLA-4), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, volrustomig targets and binds to both PD-1 and CTLA4 expressed on tumor-infiltrating T lymphocytes (TILs), and inhibits the PD-1- and CTLA4-mediated downregulation of T-cell activation and proliferation. Currently, the drug is in Phase III stage of its clinical trial for the treatment of Mesothelioma.

• Tremelimumab: MedImmune LLC

Tremelimumab is a type of monoclonal antibody and a type of immune checkpoint inhibitor. It is a drug that binds to the protein CTLA-4 to help immune cells kill cancer cells better and is used to treat different types of cancer. Tremelimumab is directed against cytotoxic T- lymphocyte-associated protein 4 (CTLA-4). By blocking the activity of CTLA-4, tremelimumab “releases the brakes” on T cell activation and boosts the immune response against cancer cells. It is a fully human monoclonal antibody, which stimulates the immune system to destroy cancer cells through binding to the protein CTLA-4, expressed on the surface of activated T-lymphocytes. Tremelimumab has been granted Orphan Drug Designation and Fast Track Designation form the US Food and Drug Administration. Currently, the drug is in Phase II stage of its clinical trial for the treatment of Mesothelioma.

• TAK-500: Takeda

TAK-500 is a first-in-class STING agonist immunostimulatory antibody drug conjugate (iADC) that delivers dazostinag to CCR2+ myeloid cells in the tumor microenvironment. By targeting the STING pathway and CCR2 expressing myeloid cells, TAK-500 may offer enhanced potency via improved PK and selective delivery. TAK-500 has three possible mechanisms of action: activation of IFN response, reprogramming of suppressive intratumoral CCR2+ myeloid cells, and blockade of suppressive tumor-associated macrophage recruitment. Activation of STING leads to the production of proinflammatory cytokines that activate dendritic cells, macrophages, and natural killer cells, and subsequently mobilize adaptive immune cells against tumor cells. Combining TAK-500 with radiation and/or checkpoint inhibitors led to enhanced antitumor activity in preclinical studies. Dying tumor cells release tumor antigens and tumor-derived cGAMP, which continue to activate the STING pathway. Currently, the drug is in Phase I/II stage of its clinical trial for the treatment of Mesothelioma.

• RSO-021: RS Oncology LLC

RSO-021 is a naturally occurring, sulfur-rich, cyclic oligopeptide of the thiopeptide class, which covalently inactivates PRX3, leading to catastrophic oxidative stress and cell death. It is a novel first-in-class small molecule that irreversibly binds and inhibits mitochondrial peroxiredoxin 3 (PRX3). Inhibition of the PRX3 antioxidant signaling network in mitochondria results in selective killing of malignant cells by upregulation of oxidative stress; in contrast, healthy tissue is spared. In pre-clinical models RSO-021 reduces tumor growth in mice, sensitizes tumor cells to apoptosis and reduces the expression of pro-metastatic epithelial to mesenchymal (EMT) genes. Currently, the drug is in Phase I/II stage of its clinical trial for the treatment of Mesothelioma.

The Mesothelioma Pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Mesothelioma with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Mesothelioma Treatment.
• Mesothelioma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Mesothelioma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Mesothelioma market.

From early-stage research to late-phase Mesothelioma Clinical Trials, our analysis covers key companies, innovative treatment approaches, and the next wave of Emerging Drugs. Don’t miss this opportunity to stay informed—download now! @ Mesothelioma Treatment Drugs

Mesothelioma Companies

Polaris Pharmaceuticals, AstraZeneca, MedImmune LLC, Takeda, RS Oncology LLC, Vivace Therapeutics, Inc., VM Oncology, LLC, KaliVir Immunotherapeutics, UTC Therapeutics Inc., Tango Therapeutics, Inc., Verismo Therapeutics, SpringWorks Therapeutics, Inc., Gilead Sciences, Nurix Therapeutics, Inc., Amphera BV, Merck Sharp & Dohme LLC, Constellation Pharmaceuticals, BridGene Biosciences Inc., Aromics Therapeutics, and Ascentage Pharma Group Inc. and others.

Mesothelioma Pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Mesothelioma Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Stay updated with the latest Mesothelioma Pipeline Insights—download our report for a deep dive into the next generation of therapeutics! @ Mesothelioma Market Drivers and Barriers, and Future Perspectives

Scope of the Mesothelioma Pipeline Report

• Coverage- Global
• Mesothelioma Companies- Polaris Pharmaceuticals, AstraZeneca, MedImmune LLC, Takeda, RS Oncology LLC, Vivace Therapeutics, Inc., VM Oncology, LLC, KaliVir Immunotherapeutics, UTC Therapeutics Inc., Tango Therapeutics, Inc., Verismo Therapeutics, SpringWorks Therapeutics, Inc., Gilead Sciences, Nurix Therapeutics, Inc., Amphera BV, Merck Sharp & Dohme LLC, Constellation Pharmaceuticals, BridGene Biosciences Inc., Aromics Therapeutics, and Ascentage Pharma Group Inc. and others
• Mesothelioma Therapies- Pembrolizumab, Lenvatinib, Nivolumab, Ipilimumab, ZD1839, Zometa, Durvalumab, and others.
• Mesothelioma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Mesothelioma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Find answers in our latest Mesothelioma Pipeline Insights report, featuring in-depth coverage of Clinical Trials, regulatory trends, and upcoming breakthroughs. Download now to stay at the forefront of pharmaceutical innovation!” @ Mesothelioma Emerging Drugs and Companies

Table of Content

1. Introduction
2. Executive Summary
3. Mesothelioma: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Mesothelioma – DelveInsight’s Analytical Perspective
7. Late Stage Products (Preregistration)
8. Pegargiminase: Polaris Pharmaceuticals
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Tremelimumab: MedImmune LLC
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I/II)
14. TAK-500: Takeda
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Mesothelioma Key Companies
21. Mesothelioma Key Products
22. Mesothelioma- Unmet Needs
23. Mesothelioma- Market Drivers and Barriers
24. Mesothelioma- Future Perspectives and Conclusion
25. Mesothelioma Analyst Views
26. Mesothelioma Key Companies
27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/mesothelioma-pipeline-insight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Mesothelioma Pipeline Outlook Report 2025: Key 45+ Companies and Breakthrough Therapies Shaping the Future Landscape

DelveInsight’s, “Marginal Zone Lymphoma Pipeline Insight 2025” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Marginal Zone Lymphoma pipeline landscape. It covers the Marginal Zone Lymphoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Marginal Zone Lymphoma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Stay ahead with the latest insights! Download DelveInsight’s comprehensive Marginal Zone Lymphoma Pipeline Report to explore emerging therapies, key companies, and future treatment landscapes @ Marginal Zone Lymphoma Pipeline Outlook Report

Key Takeaways from the Marginal Zone Lymphoma Pipeline Report

• In August 2025, Genmab announced a trial is an open-label, multi-center safety and preliminary efficacy trial of epcoritamab (EPKINLY™) in Japanese participants with relapsed, progressive or refractory B-cell lymphomas and Japanese participants with B-cell lymphomas that have achieved partial response (PR) or complete response (CR) following prior standard of care (SOC). The trial consists of two parts: Part 1, dose escalation (phase 1), and Part 2, expansion (phase 2).
• In August 2025, BeiGene conducted a Phase 1/2 study of zanubrutinib in Japanese participants with mature B-cell malignancies. This study intends to assess the use of zanubrutinib as an investigational agent to develop new treatment options for Japanese participants with B-cell malignancies. No formal hypothesis testing will be performed given the small sample size.
• In August 2025, H. Lee Moffitt Cancer Center and Research Institute announced a study is to establish the safety and efficacy of zanubrutinib in combination with rituximab for people with untreated B-cell lymphomas (marginal zone lymphoma and follicular lymphomas).
• DelveInsight’s Marginal Zone Lymphoma pipeline report depicts a robust space with 50+ active players working to develop 50+ pipeline therapies for Marginal Zone Lymphoma treatment.
• The leading Marginal Zone Lymphoma Companies such as Incyte Corporation, HUTCHMED, InnoCare Pharma, ENTEROME SA, Beijing Mabworks Biotech Co., Ltd., ADC Therapeutics, MEI Pharma, Inc., Genentech, Inc., Novartis, AstraZeneca, Kite Pharma, Roche, Oncternal Therapeutics, Inc., Celgene, IGM Biosciences, Inc., Loxo Oncology, Genmab, ArQule, Sound Biologics, Adicet Bio, Inc., Celldex Therapeutics, TG Therapeutics, Inc., VelosBio Inc., Newave Pharmaceutical Inc., Boryung Pharmaceutical Co., Ltd., Cellectar Biosciences, Inc., Bio-Path Holdings, Inc., Nurix Therapeutics, Inc. and others.
• Promising Marginal Zone Lymphoma Therapies such as Pirtobrutinib, Obinutuzumab, Loncastuximab tesirine 150 µg/Kg, Copanlisib, Rituximab, Venetoclax, and others.

Discover how the Marginal Zone Lymphoma treatment paradigm is evolving. Access DelveInsight’s in-depth Pipeline Analysis for a closer look at promising breakthroughs @ Marginal Zone Lymphoma Clinical Trials and Studies

Marginal Zone Lymphoma Emerging Drugs

• Tafasitamab: Incyte Corporation

Tafasitamab is an investigational humanized Fc-engineered monoclonal antibody directed against CD19. In 2010, MorphoSys licensed exclusive worldwide rights to develop and commercialize tafasitamab from Xencor, Inc. Tafasitamab incorporates an XmAb® engineered Fc domain, which is intended to lead to a significant potentiation of antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP), thus aiming to improve a key mechanism of tumor cell killing. The therapy is currently in Phase III stage of clinical trial evaluation to treat Marginal Zone Lymphoma.

• Amdizalisib (HMPL-689): HUTCHMED

The investigational drug candidate amdizalisib is a novel, selective small molecule inhibitor targeting the isoform phosphoinositide 3’-kinase delta (PI3Kδ), a key component in the B-cell receptor signaling pathway. We have designed amdizalisib with increased PI3Kδ isoform selectivity. Amdizalisib’s pharmacokinetic properties have been found to be favorable with good oral absorption, moderate tissue distribution and low clearance in pre-clinical pharmacokinetic studies. Amdizalisib is being investigated in studies in the U.S., Europe, China and Australia in various subtypes of advanced relapsed or refractory non-Hodgkin’s lymphoma, including follicular lymphoma and marginal zone lymphoma.

• Orelabrutinib: InnoCare Pharma

Orelabrutinib is a small molecule Bruton’s tyrosine kinase inhibitor (BTKi) developed for the treatment of cancer and in development for the potential treatment of autoimmune diseases. In the field of oncology, InnoCare received approval for orelabrutinib from the China National Medical Products Administration (NMPA) in two indications: the treatment of patients with relapsed/refractory chronic lymphocytic leukemia (R/R CLL)/small lymphocytic lymphoma (R/R SLL), and the treatment of patients with relapsed/refractory mantle cell lymphoma (R/R MCL). Currently, it is in Phase II stage of clinical trial evaluation to treat Marginal Zone Lymphoma (MZL).

• EO2463: Enterome

EO2463 is an innovative, off-the-shelf microbiome-peptide based cancer vaccine that combines four microbiome-peptides of B lymphocyte-specific lineage markers. EO2463 is designed to trigger the immune system into recognizing B cells as bacterial (i.e. non-self) and eliciting a targeted cell-killing response. The clinical rationale behind targeting these specific lineage cell markers is to induce the full depletion of malignant B lymphocytes that cause NHL.

The Marginal Zone Lymphoma pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Marginal Zone Lymphoma with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Marginal Zone Lymphoma Treatment.
• Marginal Zone Lymphoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Marginal Zone Lymphoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Marginal Zone Lymphoma market.

Get a detailed analysis of the latest innovations in the Marginal Zone Lymphoma pipeline. Explore DelveInsight’s expert-driven report today! @ Marginal Zone Lymphoma Unmet Needs

Marginal Zone Lymphoma Companies

Incyte Corporation, HUTCHMED, InnoCare Pharma, ENTEROME SA, Beijing Mabworks Biotech Co., Ltd., ADC Therapeutics, MEI Pharma, Inc., Genentech, Inc., Novartis, AstraZeneca, Kite Pharma, Roche, Oncternal Therapeutics, Inc., Celgene, IGM Biosciences, Inc., Loxo Oncology, Genmab, ArQule, Sound Biologics, Adicet Bio, Inc., Celldex Therapeutics, TG Therapeutics, Inc., VelosBio Inc., Newave Pharmaceutical Inc., Boryung Pharmaceutical Co., Ltd., Cellectar Biosciences, Inc., Bio-Path Holdings, Inc., Nurix Therapeutics, Inc. and others.

Marginal Zone Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous

Marginal Zone Lymphoma Products have been categorized under various Molecule types such as

• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine

Download DelveInsight’s latest report to gain strategic insights into upcoming Marginal Zone Lymphoma Therapies and key drugs developments @ Marginal Zone Lymphoma Market Drivers and Barriers, and Future Perspectives

Scope of the Marginal Zone Lymphoma Pipeline Report

• Coverage- Global
• Marginal Zone Lymphoma Companies-Incyte Corporation, HUTCHMED, InnoCare Pharma, ENTEROME SA, Beijing Mabworks Biotech Co., Ltd., ADC Therapeutics, MEI Pharma, Inc., Genentech, Inc., Novartis, AstraZeneca, Kite Pharma, Roche, Oncternal Therapeutics, Inc., Celgene, IGM Biosciences, Inc., Loxo Oncology, Genmab, ArQule, Sound Biologics, Adicet Bio, Inc., Celldex Therapeutics, TG Therapeutics, Inc., VelosBio Inc., Newave Pharmaceutical Inc., Boryung Pharmaceutical Co., Ltd., Cellectar Biosciences, Inc., Bio-Path Holdings, Inc., Nurix Therapeutics, Inc. and others.
• Marginal Zone Lymphoma Therapies- Pirtobrutinib, Obinutuzumab, Loncastuximab tesirine 150 µg/Kg, Copanlisib, Rituximab, Venetoclax, and others.
• Marginal Zone Lymphoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Marginal Zone Lymphoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Which companies are leading the race in Marginal Zone Lymphoma drug development? Find out in DelveInsight’s exclusive pipeline report—access it now! @ Marginal Zone Lymphoma Emerging Drugs and Major Companies

Table of Content

1. Introduction
2. Executive Summary
3. Marginal Zone Lymphoma: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Marginal Zone Lymphoma – DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Tafasitamab: Incyte Corporation
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. Orelabrutinib: InnoCare Pharma
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I/II)
14. EO2463: Enterome
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug name: Company name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Marginal Zone Lymphoma Key Companies
21. Marginal Zone Lymphoma Key Products
22. Marginal Zone Lymphoma- Unmet Needs
23. Marginal Zone Lymphoma- Market Drivers and Barriers
24. Marginal Zone Lymphoma- Future Perspectives and Conclusion
25. Marginal Zone Lymphoma Analyst Views
26. Marginal Zone Lymphoma Key Companies
27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/marginal-zone-lymphoma-pipeline-insight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Marginal Zone Lymphoma Pipeline Outlook Report 2025: Key 50+ Companies and Breakthrough Therapies Shaping the Future Landscape

DelveInsight’s, “Esophageal Squamous Cell Carcinoma Pipeline Insights 2025” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Esophageal Squamous Cell Carcinoma pipeline landscape. It covers the Esophageal Squamous Cell Carcinoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Esophageal Squamous Cell Carcinoma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore the comprehensive insights by DelveInsight and stay ahead in understanding the Esophageal Squamous Cell Carcinoma Treatment Landscape. Click here to read more @ Esophageal Squamous Cell Carcinoma Pipeline Outlook

Key Takeaways from the Esophageal Squamous Cell Carcinoma Pipeline Report

• In August 2025, Yuhan Corporation conducted a study for people with locally advanced or metastatic cancer for whom previous treatment was not successful. Adults aged 18 and over with advanced cancer with Epidermal Growth Factor Receptor (EGFR) overexpressing can join the study. The purpose of this study is to find out whether a medicine called YH32364 helps people with locally advanced or metastatic cancers with EGFR overexpression.
• In July 2025, Daiichi Sankyo conducted a study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXd) in patients with unresectable advanced or metastatic esophageal squamous cell carcinoma (ESCC) who have experienced disease progression following treatment with a platinum-based systemic therapy and an immune checkpoint inhibitor (ICI) compared with investigator’s choice of chemotherapy (ICC).
• In July 2025, Hoffmann-La Roche announced a study is to evaluate the efficacy and safety of tiragolumab plus atezolizumab compared with placebo in participants with unresectable esophageal squamous cell carcinoma (or those who are unable or unwilling to undergo surgery) and whose cancers have not progressed following definitive concurrent chemoradiotherapy (dCRT). Participants will be randomized in a 1:1:1 ratio to receive either tiragolumab plus atezolizumab (Arm A), tiragolumab matching placebo plus atezolizumab (Arm B), or double placebo (Arm C).
• DelveInsight’s Esophageal Squamous Cell Carcinoma pipeline report depicts a robust space with 50+ active players working to develop 50+ pipeline therapies for Esophageal Squamous Cell Carcinoma treatment.
• The leading Esophageal Squamous Cell Carcinoma Companies such as BeiGene, Shanghai Henlius Biotech, CStone Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., AstraZeneca, Servier, Hoffmann-La Roche, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Sinocelltech Ltd., Eli Lilly and Company, Ipsen, Jacobio Pharmaceuticals Co., Ltd., Shire, GlaxoSmithKline, Keythera Pharmaceuticals (Australia) Pty Ltd, Sunshine Lake Pharma Co., Ltd., Novartis Pharmaceuticals, Sanofi, Seagen Inc., Rapa Therapeutics LLC, Incyte Corporation, Atreca, Inc., Eli Lilly and Company, Exelixis, Symphogen A/S, Bayer, Eisai Inc., and others.
• Promising Esophageal Squamous Cell Carcinoma Therapies such as Camrelizumab, SI-B001, Irinotecan, Paclitaxel, Cisplatin, JMT101, and others.

Discover groundbreaking developments in Esophageal Squamous Cell Carcinoma therapies! Gain in-depth knowledge of key clinical trials, emerging drugs, and market opportunities @ Esophageal Squamous Cell Carcinoma Clinical Trials Assessment

Esophageal Squamous Cell Carcinoma Emerging Drugs Profile

• Tislelizumab: BeiGene

Tislelizumab (BGB-A317) is a humanized IgG4 anti–PD-1 monoclonal antibody specifically designed to minimize binding to FcγR on macrophages. In pre-clinical studies, binding to FcγR on macrophages has been shown to compromise the anti-tumor activity of PD-1 antibodies through activation of antibody-dependent macrophage-mediated killing of T effector cells. Tislelizumab is the first drug candidate produced from BeiGene’s immuno-oncology biologic program, and we believe it could serve as a key element of our immuno-oncology combination platform. Tislelizumab is being developed as a monotherapy and in combination with other therapies for the treatment of a broad array of both solid tumor and hematologic cancers. Currently, it is in Phase III stage of clinical trial evaluation to treat Esophageal Squamous Cell Carcinoma.

• Serplulimab: Shanghai Henlius Biotech

Serplulimab (novel anti-PD-1 mAb) is the first innovative monoclonal antibody (mAb) developed by Henlius. Shanghai Henlius Biotech, announced that the phase 3 clinical study ASTRUM-007 of HANSIZHUANG (serplulimab) independently developed by the company in combination with chemotherapy as a first-line treatment for patients with locally advanced/metastatic esophageal squamous cell carcinoma (ESCC), met the co-primary endpoints of progression-free survival (PFS) and overall survival (OS) in a planned interim analysis, evaluated by the Independent Data Monitoring Committee (IDMC).

The Esophageal Squamous Cell Carcinoma Pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Esophageal Squamous Cell Carcinoma with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Esophageal Squamous Cell Carcinoma Treatment.
• Esophageal Squamous Cell Carcinoma Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Esophageal Squamous Cell Carcinoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Esophageal Squamous Cell Carcinoma market.

Stay informed about the Esophageal Squamous Cell Carcinoma pipeline trends! Uncover critical updates on therapeutic innovations and their potential impact on patients and the healthcare industry @ Esophageal Squamous Cell Carcinoma Unmet Needs

Esophageal Squamous Cell Carcinoma Companies

BeiGene, Shanghai Henlius Biotech, CStone Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., AstraZeneca, Servier, Hoffmann-La Roche, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Sinocelltech Ltd., Eli Lilly and Company, Ipsen, Jacobio Pharmaceuticals Co., Ltd., Shire, GlaxoSmithKline, Keythera Pharmaceuticals (Australia) Pty Ltd, Sunshine Lake Pharma Co., Ltd., Novartis Pharmaceuticals, Sanofi, Seagen Inc., Rapa Therapeutics LLC, Incyte Corporation, Atreca, Inc., Eli Lilly and Company, Exelixis, Symphogen A/S, Bayer, Eisai Inc., and others.

Esophageal Squamous Cell Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• NA
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous

Esophageal Squamous Cell Carcinoma Products have been categorized under various Molecule types such as

• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine

Transform your understanding of the Esophageal Squamous Cell Carcinoma Pipeline! See the latest progress in drug development and clinical research @ Esophageal Squamous Cell Carcinoma Market Drivers and Barriers, and Future Perspectives

Scope of the Esophageal Squamous Cell Carcinoma Pipeline Report

• Coverage- Global
• Esophageal Squamous Cell Carcinoma Companies- BeiGene, Shanghai Henlius Biotech, CStone Pharmaceuticals, Jiangsu HengRui Medicine Co., Ltd., AstraZeneca, Servier, Hoffmann-La Roche, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Sinocelltech Ltd., Eli Lilly and Company, Ipsen, Jacobio Pharmaceuticals Co., Ltd., Shire, GlaxoSmithKline, Keythera Pharmaceuticals (Australia) Pty Ltd, Sunshine Lake Pharma Co., Ltd., Novartis Pharmaceuticals, Sanofi, Seagen Inc., Rapa Therapeutics LLC, Incyte Corporation, Atreca, Inc., Eli Lilly and Company, Exelixis, Symphogen A/S, Bayer, Eisai Inc., and others.
• Esophageal Squamous Cell Carcinoma Therapies- Camrelizumab, SI-B001, Irinotecan, Paclitaxel, Cisplatin, JMT101, and others.
• Esophageal Squamous Cell Carcinoma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Esophageal Squamous Cell Carcinoma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Stay Ahead in Oncology Research–Access the Full Esophageal Squamous Cell Carcinoma Pipeline Analysis Today! @ Esophageal Squamous Cell Carcinoma Drugs and Companies

Table of Content

1. Introduction

2. Executive Summary

3. Esophageal Squamous Cell Carcinoma: Overview

4. Pipeline Therapeutics

5. Therapeutic Assessment

6. Esophageal Squamous Cell Carcinoma – DelveInsight’s Analytical Perspective

7. Late Stage Products (Phase III)

8. Tislelizumab: BeiGene

9. Drug profiles in the detailed report…..

10. Mid Stage Products (Phase II)

11. RAPA-201: Rapa Therapeutics

12. Drug profiles in the detailed report…..

13. Early Stage Products (Phase I)

14. SGN-B6A: Seagen

15. Drug profiles in the detailed report…..

16. Preclinical and Discovery Stage Products

17. Drug name: Company name

18. Drug profiles in the detailed report…..

19. Inactive Products

20. Esophageal Squamous Cell Carcinoma Key Companies

21. Esophageal Squamous Cell Carcinoma Key Products

22. Esophageal Squamous Cell Carcinoma- Unmet Needs

23. Esophageal Squamous Cell Carcinoma- Market Drivers and Barriers

24. Esophageal Squamous Cell Carcinoma- Future Perspectives and Conclusion

25. Esophageal Squamous Cell Carcinoma Analyst Views

26. Esophageal Squamous Cell Carcinoma Key Companies

27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/esophageal-squamous-cell-carcinoma-pipeline-insight

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Esophageal Squamous Cell Carcinoma Pipeline Outlook Report 2025: Key 50+ Companies and Breakthrough Therapies Shaping the Future Landscape